JP2025505141A - Ｍｃｌ－１阻害剤の結晶形態 - Google Patents

Ｍｃｌ－１阻害剤の結晶形態 Download PDF

Info

Publication number
JP2025505141A
JP2025505141A JP2024545807A JP2024545807A JP2025505141A JP 2025505141 A JP2025505141 A JP 2025505141A JP 2024545807 A JP2024545807 A JP 2024545807A JP 2024545807 A JP2024545807 A JP 2024545807A JP 2025505141 A JP2025505141 A JP 2025505141A
Authority
JP
Japan
Prior art keywords
crystalline form
radiation
xrpd pattern
amg
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505141A5 (enExample
Inventor
ケリー，ロン・シー
チャベス，メアリー
テン，ジン
ペアレント，スティーブン
ステック，マーキアン
ルー，バン
ファレル，ロバート・ピー
ハックル，ジェームズ・イー
アフマトビッチ，ミハウ
ウー，ティアン
リード，ダーレン・エル
シャオ，リンユン
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2025505141A publication Critical patent/JP2025505141A/ja
Publication of JP2025505141A5 publication Critical patent/JP2025505141A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2024545807A 2022-02-04 2023-02-03 Ｍｃｌ－１阻害剤の結晶形態 Pending JP2025505141A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306776P 2022-02-04 2022-02-04
US63/306,776 2022-02-04
PCT/US2023/012251 WO2023150249A1 (en) 2022-02-04 2023-02-03 Crystalline forms of an mcl-1 inhibitor

Publications (2)

Publication Number Publication Date
JP2025505141A true JP2025505141A (ja) 2025-02-21
JP2025505141A5 JP2025505141A5 (enExample) 2026-02-06

Family

ID=85570021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545807A Pending JP2025505141A (ja) 2022-02-04 2023-02-03 Ｍｃｌ－１阻害剤の結晶形態

Country Status (7)

Country Link
US (1) US20250115622A1 (enExample)
EP (1) EP4472984A1 (enExample)
JP (1) JP2025505141A (enExample)
AU (1) AU2023216691A1 (enExample)
CA (1) CA3246092A1 (enExample)
MX (1) MX2024009448A (enExample)
WO (1) WO2023150249A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4519271A1 (en) 2022-05-04 2025-03-12 Gilead Sciences, Inc. Salts and polymorphs of certain mcl-1 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
JP2021161114A (ja) * 2020-03-31 2021-10-11 アムジエン・インコーポレーテツド Ｍｃｌ−１化合物のメチル化

Also Published As

Publication number Publication date
CA3246092A1 (en) 2023-08-10
US20250115622A1 (en) 2025-04-10
EP4472984A1 (en) 2024-12-11
MX2024009448A (es) 2024-08-15
AU2023216691A1 (en) 2024-07-04
WO2023150249A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
CN107056813B (zh) 德罗格韦钠盐的晶型及其制备方法
JP7825636B2 (ja) （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
EP2752414A1 (en) Crystalline form of apixaban
JP2025505141A (ja) Ｍｃｌ－１阻害剤の結晶形態
KR20240119095A (ko) Fgfr 저해제의 고체 상태 형태
US20240140966A1 (en) Amorphous and crystalline forms of mcl-1 antagonists
JP2021518375A (ja) アベマシクリブの固相形態、その使用及び調製
US20250122224A1 (en) Crystalline Salt and Solvate Forms Of Murizatoclax (AMG 397)
EP4504737A1 (en) Salt forms and solvates of mci-1 antagonists
KR20010074473A (ko) 형태 Ⅵ의 5,6-디클로로-2-(이소프로필아미노)-1-(β-Ｌ-리보푸라노실)-1Ｈ-벤즈이미다졸
CN116514775B (zh) 一种徳拉沙星葡甲胺盐新晶型及其制备方法
KR20250132529A (ko) 리나프라잔 글루레이트의 하이드로브로마이드 염의 다형체
KR20240093547A (ko) 리나프라잔 글루레이트의 메실레이트 염의 다형체
CN115803329A (zh) 八氢噻吩并喹啉化合物的琥珀酸盐及其晶体
EP4349835A1 (en) Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof
JP7282787B2 (ja) ピラゾロ［３，４－ｄ］ピリミジンの結晶
JP2026503096A (ja) リナプラザングルレート（ｌｉｎａｐｒａｚａｎ ｇｌｕｒａｔｅ）のマレイン酸塩の多形
TW202423429A (zh) 1-(8-溴化吡啶并[2,3-e][1,2,4]三唑并[4,3-a]吡嗪-4-基)-n-甲基吖丁啶-3-胺之鹽及結晶形式之製備方法以及新穎的結晶形式
JP2019514862A (ja) （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形
TW202428578A (zh) １－（８－溴化吡啶并［２，３－ｅ］［１，２，４］三唑并［４，３－ａ］吡嗪－４－基）－ｎ－甲基吖丁啶－３－胺之新穎結晶型

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260129